Perampanel (trade name: Fycompa) has been approved in Germany since July 2012 as an add-on therapy for treating epileptic seizures in adults and children over the age of 12.
Epileptic seizures are triggered by abnormal activity in the nerve cells of the brain. Epileptic seizures can cause reduced consciousness, altered awareness, and muscle twitching, as well as severe cramps and discomfort. A seizure usually lasts between a few seconds and a few minutes.
Epileptic seizures are classified as either partial or generalized, depending on how far-reaching they are. Generalized seizures affect the entire body. Partial (or focal) seizures only affect a small part of the brain, with muscle twitching and cramps only occurring in certain parts of the body. Partial seizures can however spread across the whole body – this is called a “secondary generalization.” Perampanel is approved for the treatment of partial seizures with or without secondary generalization in people aged 12 years and over.
Perampanel is used in addition to standard treatment. The drug is taken once a day in tablet form before going to bed. An individual dose will be prescribed at the start of treatment.
There are a number of add-on therapy options that can be used to treat focal seizures depending on the individual circumstances. These drugs include pregabalin, valproic acid, levetiracetam and gabapentin.
In 2014, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) last assessed what benefits perampanel has compared with other treatments that may be an option in individual cases.
However, no data on how perampanel compares with other suitable drugs was available to IQWiG.
This text summarizes the most important results of two reviews produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The reviews were commissioned by the German Federal Joint Committee (G-BA) as part of the "early benefit assessment of medications." On the basis of the reviews and the hearings received, the G-BA passed a resolution on the added benefits of perampanel (Fycompa).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Perampanel – Benefit assessment according to § 35a Social Code Book V. Dossier assessment A14-16. Cologne: IQWiG. August 15, 2014.
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Perampanel – Benefit assessment according to § 35a Social Code Book V. Dossier assessment A12-12. Cologne: IQWiG. December 17, 2012.
IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.